| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2005 | EP1549611A2 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 07/06/2005 | EP1549600A1 Ketones |
| 07/06/2005 | EP1549598A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| 07/06/2005 | EP1549398A1 Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| 07/06/2005 | EP1549351A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/06/2005 | EP1549349A1 Non-viral gene delivery system |
| 07/06/2005 | EP1549347A1 Modulation of immune function |
| 07/06/2005 | EP1549340A1 Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition |
| 07/06/2005 | EP1549337A1 Glycosaminoglycan-dnase combination therapy |
| 07/06/2005 | EP1549330A1 Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours |
| 07/06/2005 | EP1549327A1 Composition for treating hemorrhoids |
| 07/06/2005 | EP1549326A1 Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| 07/06/2005 | EP1549325A1 Classes of compounds that interact with gpcrs |
| 07/06/2005 | EP1549323A2 Conjugates comprising central nervous system active drug |
| 07/06/2005 | EP1549322A2 Lipid a and other carbohydrate ligand analogs |
| 07/06/2005 | EP1549321A2 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| 07/06/2005 | EP1549320A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 07/06/2005 | EP1549319A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 07/06/2005 | EP1549316A1 INHIBITORS OF TFG&bgr; |
| 07/06/2005 | EP1549315A2 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 07/06/2005 | EP1549314A1 Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons disease |
| 07/06/2005 | EP1549313A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 07/06/2005 | EP1549312A1 Sequential therapy comprising a 20(s)-camptothecin and an anthracycline |
| 07/06/2005 | EP1549311A1 Potent inhibitor of hcv serine protease |
| 07/06/2005 | EP1549310A1 Gelled laxative compositions |
| 07/06/2005 | EP1549309A2 Somatostatin analogue compounds |
| 07/06/2005 | EP1549308A1 An inhibitor of the shh signalling pathway and a testosterone supressing agent for the treatment of cancer |
| 07/06/2005 | EP1549307A2 Agent for medicamentous treatment of acute and chronic pain |
| 07/06/2005 | EP1549306A1 Substituted phenylsulfonamide inhibitors of beta amyloid production |
| 07/06/2005 | EP1549305A1 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
| 07/06/2005 | EP1549303A1 Inhibiting progressive cognitive impairment |
| 07/06/2005 | EP1549302A1 Gastrointestinal compositions comprising gaba derivatives |
| 07/06/2005 | EP1549301A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 07/06/2005 | EP1549300A2 Nitric oxide and its biomedical significance |
| 07/06/2005 | EP1549297A2 Stabilized pharmaceutical composition containing basic excipients |
| 07/06/2005 | EP1549296A1 Sustained release formulations of metformin |
| 07/06/2005 | EP1549293A1 Accelerating recovery from trauma |
| 07/06/2005 | EP1549290A1 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 07/06/2005 | EP1549278A2 M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS |
| 07/06/2005 | EP1549277A1 Induction and maintenance of tolerance to composite tissue allografts |
| 07/06/2005 | EP1549276A2 Drug eluting coatings for medical implants |
| 07/06/2005 | EP1549253A2 Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device |
| 07/06/2005 | EP1549246A2 Antibiotic microspheres for treatment of infections and osteomyelitis |
| 07/06/2005 | EP1549198A2 Thymic atrophy |
| 07/06/2005 | EP1549159A2 Beverages containing plant sterols |
| 07/06/2005 | EP1549143A2 Antibacterial pyrazole carboxylic acid hydrazides |
| 07/06/2005 | EP1549141A2 Methods and compositions for the treatment of autoimmune disorders using clofarabine |
| 07/06/2005 | EP1478338B1 Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof |
| 07/06/2005 | EP1446397B1 Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| 07/06/2005 | EP1411956B1 Use of oversulfated polysaccharides as inhibitors of hiv |
| 07/06/2005 | EP1411938B1 Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| 07/06/2005 | EP1390370A4 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/06/2005 | EP1373256B1 Ccr5 antagonists useful for treating aids |
| 07/06/2005 | EP1330254B1 Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine |
| 07/06/2005 | EP1315720B1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 07/06/2005 | EP1307188A4 Cannabinoid drugs |
| 07/06/2005 | EP1301187B1 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 07/06/2005 | EP1280809B1 Antitumoral ecteinascidin derivatives |
| 07/06/2005 | EP1244725B1 Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
| 07/06/2005 | EP1239862B1 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating tumor diseases |
| 07/06/2005 | EP1230375B1 Inhibiting gene expression with dsrna |
| 07/06/2005 | EP1220662B1 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 07/06/2005 | EP1216225B1 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 07/06/2005 | EP1212320B1 Phenylpiperazines as serotonin reuptake inhibitors |
| 07/06/2005 | EP1212049B1 Use of thiamphenicol for thetreatment of chlamydia pneumoniae infections |
| 07/06/2005 | EP1171089B1 Skin care compositions containing combination of skin care actives |
| 07/06/2005 | EP1162982B9 USE OF STABILISED OLIGONUCLEOTIDES FOR PREPARING A MEDICament WITH ANTITUMOUR ACTIVITY |
| 07/06/2005 | EP1140909B1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2005 | EP1066016B1 Poly-aminoacid derivatives and their use in compositions for treating keratinous fibres |
| 07/06/2005 | EP1045902B1 HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND METHODS OF USE FOR SAME |
| 07/06/2005 | EP1044001B1 Integrin receptor antagonists |
| 07/06/2005 | EP0904042B1 Cosmetic composition for rejuvenation of skin without skin irritation |
| 07/06/2005 | EP0776327B1 New multimerizing agents |
| 07/06/2005 | CN1636154A Di-substituted iminoheterocyclic compounds |
| 07/06/2005 | CN1636069A Method of determining a chemotherapeutic regimen based on ERCCI expression |
| 07/06/2005 | CN1636064A Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 07/06/2005 | CN1636059A Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2 |
| 07/06/2005 | CN1636021A Preparation and use of solidified oils |
| 07/06/2005 | CN1636020A Method for controlling angiogenesis in animals |
| 07/06/2005 | CN1636016A Methods to inhibit viral replication |
| 07/06/2005 | CN1636015A HCV e1e2 vaccine compositions |
| 07/06/2005 | CN1636011A Succinoylamino lactams as inhibitors and as a beta protein production |
| 07/06/2005 | CN1636009A Partial and full agonists of a1 adenosine receptors |
| 07/06/2005 | CN1636008A Macrolide antiinfective agents |
| 07/06/2005 | CN1636007A Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 07/06/2005 | CN1636006A Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
| 07/06/2005 | CN1636005A Benzothiazinone and benzoxazinone compounds |
| 07/06/2005 | CN1636004A Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |
| 07/06/2005 | CN1636002A Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide |
| 07/06/2005 | CN1636000A 5-substituted arylpyrimidines |
| 07/06/2005 | CN1635998A Tricyclic analgesics |
| 07/06/2005 | CN1635996A Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside |
| 07/06/2005 | CN1635979A IL-8 receptor antagonists |
| 07/06/2005 | CN1635923A Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 07/06/2005 | CN1635912A Targeted delivery of drugs for the treatment of parasitic infections |
| 07/06/2005 | CN1635911A Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 07/06/2005 | CN1635909A Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
| 07/06/2005 | CN1635908A Antibodies that immunospecifically bind to trail receptors |
| 07/06/2005 | CN1635907A Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 07/06/2005 | CN1635903A Protease inhibitors |